- Halozyme Therapeutics (HALO) is selling $100M worth of shares to finance its drug R&D programs, including "potential acceleration" of its PEGPH20 tumor drug development efforts, as well as "general corporate purposes." Underwriters have a $15M overallotment option.
- At current levels, the offering stands to increase Halozyme's share count by 6%. The company had $65.3M in cash/investments at the end of September, and $32.3M in debt.
From other sites
at 4-traders.com (Mar 23, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 9, 2015)
at Benzinga.com (Jan 8, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs